Status:
TERMINATED
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
Graves Ophthalmopathy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Autoimmune ophthalmopathy is clinically evident in one third of Graves' disease cases. In most cases it is mild; however, in 3 to 5% of cases it has a severe presentation. At present, the treatment is...
Eligibility Criteria
Inclusion
- Women or men
- Between 18 and 45 years
- Autoimmune hyperthyroidism with one year or less of evolution
- No previous treatment
- Mild to moderate ophthalmopathy
Exclusion
- Smoking
- Severe ophthalmopathy
- Steroid treatment
- Asthma
- Diabetes or other significant disease
- Creatine \>1.5 mg/dl
- Women with child bearing potential not using a birth control method
- Opthalmologic diseases
- Uncontrolled hypertension
- History of ischemic cardiopathy
- History of stroke
- History of gastrointestinal bleeding
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01893450
Start Date
June 1 2008
End Date
June 1 2013
Last Update
July 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico City, Mexico, 14000